RyCarma Therapeutics

ARMGO Pharma, Inc., founded in Tarrytown, United States, is a privately owned, venture-backed biotech company focused on developing small-molecule therapeutics for debilitating cardiac, muscular, and neurological disorders. The company's core mission is to treat diseases related to leaky Ryanodine Receptor (RyR) calcium channels. ARMGO Pharma holds an exclusive worldwide license from Columbia University for its RyR technology and know-how. Their primary focus is on orphan diseases, including the life-threatening cardiac condition Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT).

Notable affiliated individuals include scientists and researchers from Columbia University, who contribute to the development of their proprietary technology. ARMGO Pharma has attracted significant venture capital investment, underscoring confidence in their innovative approach. Key achievements include the development of promising drug candidates that have shown efficacy in preclinical models. The company's impact lies in its potential to offer new treatment options for patients suffering from rare and severe RyR-related diseases, addressing significant unmet medical needs.